Guardant360® Campaign
Home » Guardant360® Campaign

GH AMEA on Social MediaGuardant360® Campaign
Guardant360® Campaign
Guardant360® Campaign
LinkedIn

Join us at our poster display session at ESMO Asia 2019 on 23 Nov 2019 in Suntec Singapore Convention & Exhibition Centre from 6pm to 7pm and learn more about Guardant360®, the global leader in liquid biopsy.

374P – Circulating Tumor DNA (ctDNA) Identifies Actionable Genetic Alterations in Middle Eastern and Asian (MEA) Patients Diagnosed with Carcinoma of Unknown Primary (CUP)

N. Peled et al, Ben-Gurion University, Beer Sheva, IL

499P – Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong

O.S.H. Chan et al, Hong Kong Integrated Oncology Centre, HK

518P – Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA Next Generation Sequencing in advanced non-small cell lung cancer.

B.C. Ahn et al, Severance Hospital, Seoul, KR

Open chat
Message us